Axsome Therapeutics saw the highest growth of 0.99% in patent filings in May and 1.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.28% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Axsome Therapeutics’s patent filings and grants. Buy the databook here.
Axsome Therapeutics has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 80% grants. The United States(US), World Intellectual Property Organization(WIPO), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Axsome Therapeutics is filings its patents. Among the top granted patent authorities, Axsome Therapeutics has 80% of its grants in United States(US) and 20% in Australia(AU).
MedinCell could be the strongest competitor for Axsome Therapeutics
Patents related to addiction and rare diseases lead Axsome Therapeutics's portfolio
Axsome Therapeutics has the highest number of patents in addiction followed by, rare diseases and nanomedicine. For addiction, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Pain related patents lead Axsome Therapeutics portfolio followed by migraine, and arthritis
Axsome Therapeutics has highest number of patents in pain followed by migraine, arthritis, nausea, and polypoidal choroidal vasculopathy. For pain, nearly 15% of patents were filed and 21% of patents were granted in Q2 2024.
For comprehensive analysis of Axsome Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.